Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals develops therapies for patients with hematologic disorders and cancer. Products include Tavalisse, Rezlidhia, and GAVRETO. Rezlidhia treats relapsed or refractory AML with IDH1 mutation. GAVRETO treats metastatic RET fusion-positive lung and thyroid cancers. The company also develops R289, an oral IRAK1/4 Inhibitor, in Phase 1b trials.
Overview
Strengths
- Our discounted cash flow model points to 70% upside (target price 77.75 USD), and even our pessimistic growth scenario implies 51%: a margin of safety.
- Valued below its Biotechnology peers: P/E 2.3x vs. a median of 20.4x, P/FCF 11.1x vs. a median of 20.2x and EV/EBITDA 6.5x vs. a median of 15.6x.
- Cheaper than its own history: P/E 2.3x vs. a historical average of 69.1x, P/FCF 11.1x vs. a historical average of 68.1x and EV/EBITDA 6.5x vs. a historical average of 68.7x.
- Conservative leverage: net debt is only 0.1x EBITDA.
Weaknesses
- Unreliable cash generation: free cash flow was negative in 3 of the last 6 years.
- Unstable profitability: operating margin ranged from -45% to 43% over the last 6 years, with operating losses in 4 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 56.7% of total assets.
Key Financial Data